Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
France Targets Shein, Temu With Fast-Fashion Fees 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
| Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) | ||
| Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director Creates new Scientific Committee and nominates Thomas Südhof as Chair Appoints Fabienne Lecorvaisier as Chair of the Audit Committee PARIS, France - March 6, 2018 - At its meeting held on March 6, 2018, Sanofi's Board of Directors proposed to submit the appointment of Emmanuel Babeau as new independent director, as well as the renewal of the terms of Olivier Brandicourt, Patrick Kron and Christian Mulliez to a shareholders' vote during the general shareholders' meeting on May 2, 2018. Robert Castaigne, board member since 2000 and current Chair of the Audit Committee, will not seek a new term. Fabienne Lecorvaisier will succeed him as Chair of the Audit Committee. The Board has also created a new Scientific Committee, which will be led by Thomas Südhof. Emmanuel Babeau is Deputy Chief Executive Officer and Chief Financial Officer of Schneider Electric Group, a position he has held since April 2013. He joined Schneider Electric in 2009 as Chief Financial Officer. Before joining Schneider Electric Group, he was Group Chief Financial Officer of Pernod Ricard SA from 2003 to 2009. Emmanuel Babeau graduated from Ecole supérieure de commerce de Paris in 1989 with a degree in accounting and financial. "Throughout his career Emmanuel Babeau led successful acquisitions and developed strong financial skills with an international mindset that will be strong additions to our Board. We are confident that his contribution to Sanofi's strategy will be beneficial in bringing innovative medicines to the market," said Serge Weinberg, Chairman of the Board, Sanofi. "I would like to thank Robert Castaigne for his strong contribution to the board and as Chairman of the Audit Committee since March 2015 and wish all the best to Fabienne Lecorvaisier who will succeed him as Chair of the Audit Committee." | ||
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | ||
| Media Relations Contact Nicolas Kressmann Tel.: +33 (0)1 53 77 46 46 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] | |
| | ||
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/4a2b33c2-9625-42a2-a037-757e3c482ddc
